Compare SymBio Pharmaceuticals Ltd. with Similar Stocks
Dashboard
1
The company has declared Negative results for the last 10 consecutive quarters
- INTEREST(9M) At JPY 92.25 MM has Grown at inf%
- NET SALES(Q) At JPY 336.84 MM has Fallen at -11.67%
- ROCE(HY) Lowest at -174.65%
2
Risky - Negative EBITDA
3
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
JPY 5,353 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.68
-272.34%
3.24
Revenue and Profits:
Net Sales:
337 Million
(Quarterly Results - Dec 2025)
Net Profit:
-1,211 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
28.09%
0%
28.09%
6 Months
-18.57%
0%
-18.57%
1 Year
-34.86%
0%
-34.86%
2 Years
-39.68%
0%
-39.68%
3 Years
-73.73%
0%
-73.73%
4 Years
-85.35%
0%
-85.35%
5 Years
-90.97%
0%
-90.97%
SymBio Pharmaceuticals Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
3.58%
EBIT Growth (5y)
1.88%
EBIT to Interest (avg)
-451.43
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.86
Sales to Capital Employed (avg)
0.65
Tax Ratio
0.86%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
24.63%
ROE (avg)
9.20%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.38
EV to EBIT
-1.22
EV to EBITDA
-1.22
EV to Capital Employed
10.70
EV to Sales
2.44
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-877.08%
ROE (Latest)
-126.18%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
336.80
324.20
3.89%
Operating Profit (PBDIT) excl Other Income
-1,101.30
-1,185.40
7.09%
Interest
11.60
29.00
-60.00%
Exceptional Items
-74.70
-2.10
-3,457.14%
Consolidate Net Profit
-1,210.50
-1,196.50
-1.17%
Operating Profit Margin (Excl OI)
-3,269.40%
-3,656.60%
38.72%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is 3.89% vs -15.26% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is -1.17% vs -14.20% in Sep 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
1,307.60
2,452.90
-46.69%
Operating Profit (PBDIT) excl Other Income
-4,440.70
-3,877.00
-14.54%
Interest
149.40
0.00
Exceptional Items
-76.30
-117.50
35.06%
Consolidate Net Profit
-4,776.20
-3,833.50
-24.59%
Operating Profit Margin (Excl OI)
-3,395.90%
-1,580.60%
-181.53%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -46.69% vs -56.12% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -24.59% vs -95.31% in Dec 2024
About SymBio Pharmaceuticals Ltd. 
SymBio Pharmaceuticals Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






